- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02464709
Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)
Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)
Study Overview
Status
Intervention / Treatment
Detailed Description
Photodynamic therapy (PDT) is a widely used method in dermatology clinics for treatment of superficial skin cancers and premalignant lesions. Actinic keratoses (AKs) are premalignant skin lesions which develop due to long-lasting sun exposure and in time can progress into squamocellular skin cancer if left untreated. The incidence of AKs and skin cancers is rapidly booming as the elderly population increases in western countries. It is crucial to treat AKs early and effectively considering their tendency to progress into malign cancer. The current general consensus for treating AKs is to treat large sun-damaged skin areas simultaneously instead of separate AK lesions. Term "skin field cancerization" refers to presence of different degrees of visible and invisible dysplastic changes in widely sun-damaged skin. Natural daylight mediated photodynamic therapy (NDL-PDT) is a well-suited method for treating large field-cancerized skin areas.
In PDT a photosensitizing cream is applied on the skin and let to absorb. After absorption to the skin cells the photosensitizer changes into protoporphyrin IX (PpIX). PpIX reacts with visible light causing a phototoxic reaction which destroys cancer cells targetedly. After absorption the skin can be illuminated using a red lamp (conventional PDT) or natural daylight (NDL-PDT) as the absorption spectrum peaks of PpIX are within the visual spectrum of light.
In Finland the approved photosensitizers for PDT are methyl 5-aminolevulinate cream (MAL, Metvix®, Galderma) and aminolevulinic acid gel (BF-200 ALA, Ameluz®, Biofrontera AG). They both have been clinically studied and proved effective in conventional PDT but in NDL-PDT mainly MAL has been in focus of studies. To our knowledge there is only research report concerning the use of BF-200 ALA in NDL-PDT (Neittaanmaki-Perttu et al 2014) which is a study of our own research group. In this study BF-200 ALA appeared to be more effective than MAL.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Lahti, Finland
- Päijät-Häme Central hospital
-
Tampere, Finland
- Tampere University Hospital
-
Vaasa, Finland
- Vaasa Central Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with widespread AK lesions symmetrically on face or scalp (at least 3 actinic keratoses symmetrically on face or scalp)
- AKs of grade I-II
Exclusion Criteria:
- Thick grade III AKs
- Previous treatment for actinic keratosis on the same skin area during preceding 6 months
- Porfyria or solar dermatitis
- Allergy for photosensitizers used in the study
- Pregnant or breastfeeding patients
- Impaired general condition (patient can't manage required 2 hours in sunlight outdoors)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Actinic keratosis patients
Participant's AKs in facial skin or scalp are first clinically graded and demarcated in two symmetric treatment areas on different sides of face.
The areas will be curettaged thinly and next a SPF20 sun protection cream is applied on all sun-exposed areas of the skin.
Then a 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid) gel is applied on one treatment side and MAL (methyl 5-aminolevulinate) cream on the other side.
The sides will be randomized and the participant doesn't know which side is treated with which light sensitizer.
After appropriate absorption time of 30 minutes the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction.
Maximum dosage of light sensitizer will be 2 grams.
|
A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
Other Names:
A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical healing of actinic keratoses
Time Frame: 12 months
|
Participant's AKs in the treatment areas are counted and categorized clinically in three grades I-III (Olsen et al. 1991) before the NDL-PDT treatment.
The clinical healing of actinic keratoses will be assessed by a dermatologist 12 months after the treatment.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessing pain experienced by participants: comparing the difference in symmetrical treatment areas of face or scalp
Time Frame: 1 day
|
Participants will be asked to fill visual analogue scales (VAS) about pain experienced on both treatment sides of the face or scalp.
Pain is assessed during the DL-PDT and after the treatment until the evening.
|
1 day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary treatment reaction of skin
Time Frame: 1 week
|
The participants will come to clinic 5-7 days after treatment and nurse will photograph both treatment sides.
Primary treatment reaction of skin will be single-blindedly assessed from the photographs.
A dermatologist will assess which side of the face or scalp presents a stronger reaction.
|
1 week
|
Dermatoecological analyses of the treatment costs
Time Frame: 12 months
|
Researchers will analyze the cost-efficacy of the treatments using decision tree, sensitivity analysis, ICER and QALY-analyses to decide with treatment modality is more preferable.
The differences in cost-efficacy will most likely depend on the light sensitizer costs and their efficacy on the treated lesions.
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Janne Rasanen, Lic. Med., Päijänne Tavastia Central Hospital
- Study Director: Mari Gronroos, D.Med.Sc., Päijänne Tavastia Central Hospital
- Study Chair: Noora Neittaanmaki-Perttu, D.Med.Sc., Helsinki University Central Hospital
- Study Chair: Mari Salmivuori, Lic. Med., Päijänne Tavastia Central Hospital
- Study Chair: Leea Ylitalo, D.Med.Sc., Tampere University Hospital
- Study Chair: Johanna Hagman, D.Med.Sc., Vaasa Central Hospital, Vaasa, Finland
- Study Chair: Ida Knutar, Lic. Med., Vaasa Central Hospital, Vaasa, Finland
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Q282dnro3/2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratosis
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
Clinical Trials on Aminolevulinic Acid
-
NorthShore University HealthSystemWithdrawn
-
University of HawaiiSBI ALApromo Co., Ltd. - Strategic Business InnovatorCompletedStress | Insomnia | Irritability | Coping Behavior | Nocturnal AwakeningUnited States
-
Goldman, Butterwick, Fitzpatrick and GroffBiofrontera Bioscience GmbHNot yet recruitingSkin NeoplasmsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedPrecancerous Condition | Non-melanomatous Skin CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Precancerous ConditionUnited States
-
Shanghai Dermatology HospitalUnknown
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedGlioma | AstrocytomaUnited States
-
Laser and Skin Surgery Center of New YorkUnknownNon-melanomatous Skin CancerUnited States
-
MultiCare Health System Research InstituteTerminatedGlioma | Glioblastoma | Astrocytoma | Glioblastoma Multiforme | Malignant GliomaUnited States
-
Roswell Park Cancer InstituteCompletedNon-melanomatous Skin CancerUnited States